Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Simtriyo
Published 3 months, 3 weeks ago
Description
In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.